Eli Lilly’s Jaypirca, the first noncovalent BTK inhibitor, has won FDA approval for the first-line treatment of chronic ...

Following a spate of large-scale pharma investments in the U.S. last year, German conglomerate Bayer is advancing its own plans to expand in America, in a move the company is framing as the ...

Already sharing the load on two biosimilar assets, Teva Pharmaceutical and Samsung Bioepis have elected to take their ...

In three deals each worth $2 billion or more, AstraZeneca is investing in Summit Therapeutics with a focus on ivonescimab and ...

For biopharmaceutical commercial teams, integrating clinical support into Patient Support Programs (PSPs) is becoming a ...

With GLP-1s paving the way, a consumer shift is happening across markets for certain branded pharmaceuticals. | With GLP-1s ...

Pfizer is making moves on the dermatology and wider immunology fronts, detailing two phase 3 wins for its oral Janus kinase inhibitor, Litfulo, and a promising phase 2 update for its investigationa | ...

Genentech is turning up the volume on breast cancer conversations in its “About Damn Time” campaign with Breastcancer.org and ...

While Foundayo’s insulin-matching potential in type 2 diabetes had been established in a topline readout earlier this year, ...

In Milan this week, Novo and Eli Lilly took the stage at the European Association for the Study of Diabetes 2026 meeting with ...

Real Chemistry has created an artificial intelligence-enabled platform to improve a manual, fragmented stage of the ...

Taiho Pharmaceuticals, together with U.S.-based subsidiary Taiho Oncology, has inched closer to approval of another oral ...